Ascentage Pharma (06855): Multiple clinical advances will be presented at the 2026 American Society of Hematology (ASH) Annual Meeting, among which APG-5918 received an oral presentation.

Zhitong Finance APP News, Ascentage Pharma (06855) announced that multiple clinical and preclinical research advances of the company have been selected for the 68th American Society of Hematology (ASH) Annual Meeting, involving four products: olverembatinib (brand name: Nailike), China's first approved third-generation BCR-ABL inhibitor; lisaftoclax (brand name: Lishengtuo), China's first approved domestically developed original Bcl-2 inhibitor; the PRC2/EED inhibitor APG-5918; and the BTK degrader APG-3288. These comprehensively demonstrate the company's deep layout and global innovation strength in the field of hematologic oncology. Notably, APG-5918 received an oral presentation upon its first disclosure of clinical data.